IGC Pharma募集了234K美元, 以在第二阶段试验期间推进其阿尔茨海默氏病的IGC-AD1药物。 IGC Pharma raised $234K to advance its Alzheimer’s drug IGC-AD1 in Phase 2 trials.

IGC Pharma于2026年1月5日宣布, 通过注册直接提供779,997股,每股0.30美元, 筹得234 000美元, 用于支持IGC-AD1第二阶段的开发, IGC Pharma announced on January 5, 2026, that it raised $234,000 through a registered direct offering of 779,997 shares at $0.30 each, with proceeds supporting Phase 2 development of IGC-AD1, a cannabinoid-based therapy for agitation in Alzheimer’s dementia within the CALMA trial. 根据SEC注册的货架声明进行的融资还用于营运资本和一般公司目的. The financing, conducted under an SEC-registered shelf statement, also funds working capital and general corporate purposes. 该公司以美国纽约SE公司作为IGC进行交易,强调新投资者带来了战略经验和网络。 The company, trading on the NYSE American as IGC, emphasized that new investors bring strategic experience and networks. 更多的输油管方案针对的是氨基甲状腺质、Tau蛋白质、神经衰竭和新陈代谢紊乱,利用人工智能进行药物发现。 Additional pipeline programs target amyloid plaques, tau proteins, neurodegeneration, and metabolic disorders, leveraging AI for drug discovery. 前瞻性声明提醒注意,由于监管、临床和与AI相关的风险,实际结果可能有所不同。 Forward-looking statements caution that actual results may vary due to regulatory, clinical, and AI-related risks.